STOCK TITAN

Takeda Pharmaceutical Company (TAK) Stock News

TAK NYSE

Takeda Pharmaceutical Company Limited reports news as a Japan-based, R&D-driven biopharmaceutical company whose American depositary shares trade under TAK. Its updates center on medicines and pipeline programs in gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines, including ENTYVIO, GAMMAGARD LIQUID ERC, HYQVIA, TAK-881, zasocitinib, rusfertide and oveporexton.

Recurring developments include pivotal clinical trial data, U.S. FDA regulatory actions involving new drug applications, prescription product availability, collaboration updates, and financial reports. Takeda also reports on launch preparation, generic competition affecting established products, operating-cost discipline, foreign-exchange effects, corporate transformation initiatives and governance matters tied to its global pharmaceutical business.

Rhea-AI Summary

Takeda (NYSE:TAK) launched ORZEYFUL (oveporexton) in the United States for prescription treatment of narcolepsy type 1 in adults. The oral medicine activates orexin receptor 2 to address the orexin deficiency associated with the condition, which includes sudden loss of muscle tone known as cataplexy. The FDA approved ORZEYFUL in August 2026, pending controlled-substance classification; it has since been classified as Schedule IV.

Accredo Specialty Pharmacy, part of Evernorth Health Services, will dispense ORZEYFUL across the United States. The medicine's warnings cover insomnia, urinary frequency and urgency, and elevations in a muscle enzyme called creatine phosphokinase. ORZEYFUL also has potential for abuse and misuse. Use is contraindicated with strong CYP3A inhibitors, medicines that can increase oveporexton exposure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
none
-
Rhea-AI Summary

Takeda (NYSE:TAK) reported first-half FY2026 revenue of JPY 2,407.0 billion, alongside higher reported profit and progress on new medicines. Revenue rose 8.4% at actual exchange rates but fell 1.0% at constant exchange rates, which exclude currency movements. Operating profit rose 60.4% to JPY 406.7 billion; earnings per share rose 169.0% to JPY 193. Adjusted free cash flow fell 38.0% to JPY 325.7 billion.

Takeda raised its full-year forecast mainly for currency benefits, targeting revenue of JPY 4,700.0 billion and operating profit of JPY 453.0 billion. ORZEYFUL received approvals in the U.S., Japan and China and launched in Japan and China; its U.S. launch awaits DEA scheduling. MIMRYLO launched in the U.S. in August. Zasocitinib entered FDA Priority Review and European review after Phase 3 results showed superiority to deucravacitinib on the primary and all key secondary efficacy endpoints.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
-
Rhea-AI Summary

Takeda (TAK) reported that arcotatug tavatecan met both primary survival endpoints in its Phase 3 G-HOPE-001 advanced gastric cancer study. The trial enrolled 464 patients in Japan and China with previously treated CLDN18.2-positive gastric or gastroesophageal junction cancer.

At the September 3, 2026 cutoff, median overall survival was 10.2 months versus 6.9 months with physician-selected treatment. Median progression-free survival, measuring time without cancer worsening or death, was 7.1 versus 3.1 months; confirmed tumor response rates were 37.4% versus 7.7%. The earlier final primary progression-free survival analysis also showed a statistically significant benefit.

Grade ≥3 treatment-related adverse events occurred in 47.4% versus 55.9%; one treatment-related fatal event occurred with arcotatug tavatecan. Takeda plans a Japan regulatory filing and global Phase 3 trials in gastric and pancreatic cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
Rhea-AI Summary

Takeda (TAK) reported that ENTYVIO treatment targeting disease clearance prolonged time to first ulcerative colitis complication versus targeting symptom remission alone.

The Phase 4 VERDICT trial randomized 672 adults with moderate to severe disease. Disease clearance combines freedom from symptoms without corticosteroids with visible and microscopic gut healing. Among patients achieving their assigned targets, the primary comparison showed nearly 70% lower complication risk up to 80 weeks after target achievement (hazard ratio 0.33; 95% confidence interval 0.17–0.67; P=0.0014).

By Week 48, 400/672 patients achieved their assigned target. Time to complications was similar between the visible-healing and disease-clearance target groups. Safety through 96 weeks was generally consistent with previous data, with no new signals. Exploratory molecular findings associated with early disease clearance warrant further investigation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
-
Rhea-AI Summary

Takeda (TAK) launched ORZEYFUL (oveporexton) in Japan and China for narcolepsy type 1, giving physicians access to prescribe the treatment. The tablet activates orexin receptor 2 to address deficient orexin signaling, the biological cause of the disease. Approvals in China, the United States and Japan came within a month of each other. China approved treatment for adolescents aged 16 and older and adults; U.S. and Japanese approvals cover adults.

Takeda expects a U.S. launch next month, following completion of Drug Enforcement Administration scheduling, with regulatory submissions underway worldwide. Phase 3 studies showed improvements versus placebo in wakefulness, sleepiness, cataplexy, disease severity and quality of life across doses over 12 weeks, with p-values below 0.001. Common side effects include insomnia, urinary urgency, urinary frequency and excessive saliva.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
none
-
Rhea-AI Summary

Takeda (TAK) presented Phase 2/3 IgGNITE results showing investigational TAK-881 met its primary endpoint in primary immunodeficiency disease. In participants aged 16 years and older, TAK-881 demonstrated comparable antibody exposure to HYQVIA. It delivered the same immunoglobulin dose in 50% less volume; median one-site infusion time was 75.8 minutes versus 132 minutes with HYQVIA, while maintaining dosing every three to four weeks.

Descriptive analyses showed annualized infection rates of 2.62 versus 2.73 with HYQVIA. Treatment-emergent adverse events occurred in 56.1% versus 50.0%, with no TAK-881-related serious adverse events. Nine of 43 randomized participants discontinued across both treatment periods; none discontinued because of TAK-881-related adverse events. Takeda expects regulatory submissions in the United States, European Union and Japan in fiscal year 2026. Long-term safety evaluation continues in an extension study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
Rhea-AI Summary

Takeda (NYSE:TAK) reported Phase 3 results showing zasocitinib outperformed deucravacitinib on all primary and key secondary efficacy endpoints in plaque psoriasis. In LATITUDE Atlas, 36.5% achieved complete skin clearance at week 16 versus 13.9% with deucravacitinib. Rates of at least 90% improvement in psoriasis severity were 62.5% versus 34.0%; physician-assessed clear skin rates were 43.2% versus 18.5%. All three comparisons had p<0.001.

Among week-24 responders, up to 93% maintained skin clearance through week 52 in LATITUDE PsO 3001, a post-hoc analysis, and week 40 in PsO 3002. Itch and quality-of-life improvements began as early as week 2 and continued through week 24. No new safety signals were identified; common adverse events included respiratory infections and acne. Zasocitinib is under FDA and EMA review for moderate-to-severe plaque psoriasis; Takeda plans additional global applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
-
Rhea-AI Summary

Takeda (TAK) will present new data from its late-stage oncology pipeline and solid tumor portfolio at the ESMO Congress 2026 in Madrid, including a late-breaking Phase 3 study of arcotatug tavatecan (TAK-921) in previously treated advanced gastric or gastroesophageal junction adenocarcinoma.

The G-HOPE-001 registrational trial, run in Japan and China, may support a potential regulatory filing for this indication in Japan pending final results. Two presentations will feature TAK-928 in immunotherapy-resistant and first-line non-small cell lung cancer (NSCLC), alongside an update on the global Phase 3 MarsLight-11 study comparing TAK-928 to docetaxel and adding a new non-squamous NSCLC sub-trial. Takeda will also share clinical and real-world results for approved thoracic and gastrointestinal cancer medicines ALUNBRIG and FRUZAQLA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
-
Rhea-AI Summary

Takeda (TAK) is committing USD 22.2 million in 2026 to four new Global CSR collaborations focused on climate‑resilient health systems in low- and middle-income countries.

The new awardees are Corus International (USD 6.4m for early warning, resilient service delivery and disaster preparedness in Nepal), Humanity & Inclusion Handicap International (USD 6.1m to strengthen inclusive, climate-resilient health systems in Honduras and Peru), KNUST (USD 5.1m to ready the pharmacy workforce for climate-responsive care in Ghana) and Terre des hommes Foundation (USD 4.6m to build climate-resilient primary healthcare in Egypt and Lebanon). These commitments increase Takeda’s total Global CSR Program contributions to USD 260.9 million across 42 collaborations worldwide, with 20 currently ongoing in 42 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
Rhea-AI Summary

Takeda (TAK) received U.S. FDA Priority Review acceptance for its New Drug Application for zasocitinib (TAK-279) to treat adults with moderate-to-severe plaque psoriasis, with a PDUFA target action date in the first quarter of 2027.

The NDA is backed by pivotal global Phase 3 LATITUDE PsO 3001 and 3002 trials and the long-term LATITUDE PsO 3003 study, covering nearly 3,000 patients. At week 16, about 70% of zasocitinib-treated patients achieved clear or almost clear skin (sPGA 0/1), and 71–76% achieved PASI 75, versus 11–13% and 12% with placebo and around 30–37% with apremilast. High clearance rates were also observed at hard-to-treat sites such as scalp, nails, palms and soles. Zasocitinib was generally well tolerated, with no new safety signals identified. The EMA has accepted a marketing authorization application, and Takeda expects no significant impact on its fiscal 2027 forecast from this NDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.86%
Tags

FAQ

What is the current stock price of Takeda Pharmaceutical (TAK)?

Takeda Pharmaceutical (TAK) last closed at $21.77.

What is the market cap of Takeda Pharmaceutical (TAK)?

The market cap of Takeda Pharmaceutical (TAK) is approximately $69.6B.